20 results
The primary objective of this study is to determine whether treatment with the RePneu LVRC System results in improved exercise capacity and quality of life, as measured by improvements in the 6 Minute Walk Test (6MWT).
The primary objective is to establish the point prevalence of Airflow Limitation (AL) compatible with COPD in patients with congestive heart failure (CHF) seen in a single centre in the Netherlands.
2.1 Primary study objectiveThe primary objective of this study is to investigate the therapeutic effect of an extensively hydrolyzed protein based infant formula with a synbiotic mixture on the severity of atopic dermatitis in infants.2.2 Secondary…
Primary objective: To show that the variability of whole blood total and unbound plasma tacrolimus concentrations during the first 6 days post transplantation is larger than the variation of tacrolimus concentrations in stable clinical situation.…
The Activation of Coagulation and Inflammation in Trauma (ACIT) study is designed to identify the clinically significant mechanisms and pathways by which inflammation and coagulation are activated immediately following major trauma, and how these…
Primary objectives of the pilot study• To determine childhood cardiovascular health in offspring of PCOS mothers and to compare it with children from non-PCOS mothers.Secondary objectives of the pilot study• To compare cardiovascular risk factors…
The aim of this project is to address whether nebulized heparin:1) increases the number of ventilator*free days during 28*days in burn patients with inhalation trauma2) improves lung injury scores in burn patients with inhalation trauma3) reduces…
Research QuestionWhat is the long-term effectiveness and cost-effectiveness of self-management support via an internet based service in addition to usual care as compared to usual care alone in patients with COPD who have completed pulmonary…
* To define the characteristics of children with severe asthma and severe pre school wheeze in terms of clinical features, physiology and biomarker profiles and to compare these with patients with mild-moderate asthma and wheeze* To repeat the…
Primary Objective: 1. Will an exposure to oxygen with a PO2 = 190 kPa lead to changes primarily in DLno compared to DLco?Secondary Objectives: 1. After an exposure to oxygen with a PO2 = 190 kPa for one hour, are the changes primarily located in the…
PrimaryPart 1: - To determine the respiratory response of low and high doses of GAL-021 in conjunction with a low dose of opioids and hypercapnia in healthy subjects. Part 2: - To determine the respiratory response of low and high doses of GAL-021…
The primary objective is to evaluate whether the addition of a LABA to an ICS (FSC) therapy is non-inferior in terms of risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) compared with ICS…
Primary objective: To evaluate the non-inferiority of QVA149 110/50 µg qd as compared to concurrentadministration of QAB149 150 µg qd plus NVA237 50 µg qd in terms of its effect on trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose)…
Primary Objective: To determine whether or not our newly developed MRA with accelerometer can measure the therapy-effect of the MRA by determining the correlation of the treatment-efficacy of an MRA measured by an integrated accelerometer built in…
The primary objective of the trial is to determine the 24-hour FEV1-time profile of tiotropium + olodaterol FDC (2.5/5 µg, 5/5 µg), administered once daily by the RESPIMAT Inhaler, after 6 weeks of treatment.
Assess physiological, functional, and quality of life responses following AeriSeal System treatment compared control in patients with upper lobe predominant (ULP) heterogeneous emphysema
The aim of this extension trial is to provide BIBF 1120 treatment for all patients who have completed the 52 weeks treatment period and the follow up period in the phase III placebo controlled parent trial 1199.34, who may have experienced benefit…
The primary objective of the study is to evaluate whether the addition of LABA to ICS therapy (FSC) is non-inferior to ICS therapy alone (FP) in terms of the risk of serious asthma related events (asthma-related hospitalization, endotracheal…
The AlphaCore* is currently being used in some hospitalised COPD subjects, as adjunctive treatment to regular care. This use is conform CE and is showing diminished breathlessness in some subjects. For further investigation of these results, this…
Objective:1. To describe the prevalence and incidence of *difficult-to-treat* adult asthma in the Netherlands.2. To describe factors associated with adherence with pulmonary medication in patients with difficult-to-treat airway disease. 3. To…